Education
About Us
Working with TipRanks
Follow Us
Teleflex (TFX)
:TFX
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
3.36Last Year’s EPS
3.42Same Quarter Last Year
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -12.26%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for Teleflex, with achievements such as FDA clearance for new products and strategic initiatives offset by significant revenue declines, margin pressures, and challenges in key segments like OEM and UroLift. The impact of tariffs and declining earnings per share contributed to a cautious outlook, despite ongoing efforts to enhance shareholder value through strategic separation and acquisitions.Company Guidance
During the Teleflex First Quarter 2025 Earnings Conference Call, the company provided guidance for the fiscal year 2025, expecting adjusted constant currency revenue growth of 1% to 2%. They anticipate a negative impact from foreign exchange of $5 million, representing a 17 basis point headwind to GAAP revenue growth, and adjusted earnings per share are now expected to be between $13.20 and $13.60. The company projects a gross margin in the range of 58.25% to 59% and operating margins between 24.6% and 25%. A significant impact from newly enacted tariffs is expected, amounting to approximately $55 million, which will be recorded in cost of goods sold, and the company is exploring strategies to mitigate this exposure. Net interest expense is projected to be around $75 million, with an unchanged adjusted tax rate of approximately 13.5% and a full-year share count expectation of approximately 44.9 million shares.FDA Clearance for AC3 Intra-Aortic Balloon Pump
The AC3 range Intra-Aortic Balloon Pump received 510(k) clearance from the FDA, allowing for full market release in the U.S. and shipping to customers in Q2 2025.
Strong Performance in Vascular Access
Vascular Access revenue increased by 1.9% year-over-year to $182.4 million, led by strong growth in PICCs and solid performance in EZ-IO.
Ringer Perfusion Balloon Catheter IDE Study Results
Preliminary results for the Ringer PBC Catheter IDE Study were favorable, with a 73% primary efficacy endpoint success rate, supporting a premarket application submitted to the FDA.
Strategic Separation and Acquisition
Intention to separate Teleflex into two companies to enhance shareholder value, and acquisition of BIOTRONIK Vascular Intervention business to close by Q3 2025.
Accelerated Share Repurchase Program
Completed a $300 million accelerated share repurchase program, acquiring over 2.2 million shares at an average price of $135.23.
TFX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TFX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $136.69 | $125.54 | -8.16% |
Feb 27, 2025 | $176.72 | $138.39 | -21.69% |
Oct 31, 2024 | $233.59 | $199.67 | -14.52% |
Aug 01, 2024 | $219.07 | $233.98 | +6.81% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Teleflex (TFX) report earnings?
Teleflex (TFX) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is Teleflex (TFX) earnings time?
Teleflex (TFX) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TFX EPS forecast?
TFX EPS forecast for the fiscal quarter 2025 (Q2) is 3.36.